Register
Xarelto Approved for VTE Prevention in Acute Medical Illness |
Clinical News
eMediNexus Coverage from: 
Xarelto Approved for VTE Prevention in Acute Medical Illness
eMediNexus,  15 October 2019
remove_red_eye 499 Views
#Cardiology #Hospital Medicine #Internal Medicine #Pharmacist

2 Read Comments                

The FDA approved rivaroxaban (Xarelto) to prevent venous thromboembolism (VTE) and related deaths for at-risk acutely ill medical patients not at high risk of bleeding, Janssen announced Monday.

The approval was for the hospitalization and through discharge to a total recommended duration of 31 to 39 days… (Medpage Today)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now